Cancer News and Research

Latest Cancer News and Research

HHS 'special mailing' on health law's immediate Medicare benefits sparks GOP grumbles

CQ HealthBeat: "Education or propaganda? Or 'beyond propaganda?' The Centers for Medicare and Medicaid Services announced Monday that it will soon send Medicare beneficiaries a special mailing on 'the immediate benefits they may see' from the health care overhaul law. Getting accurate information about key provisions of the law will help Medicare enrollees 'to be on the alert for any scams asking for personal information,' explained acting CMS Administrator Marilyn Tavenner in an agency news release Monday.

25 May 2010

BIO praises Obama Administration’s dissemination of Therapeutic Discovery Project Program

The Biotechnology Industry Organization (BIO) praised the Obama Administration for its new guidance, released today, that will lead to many small biotechnology companies receiving needed funding to support critical on-going research and development programs. The guidance document initiates the Therapeutic Discovery Project Program (TDPP), which was created by the Patient Protection and Affordable Care Act signed into law by President Obama on March 23.

25 May 2010

CCO announces 2010 Research Chairs program

Six Ontario Researchers have received funding of $500,000 OR $1 million to further cancer research over the next five years, Cancer Care Ontario's Research Program announced today.

25 May 2010

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

A new way to deliver cancer-fighting drugs using tiny particles made from lipids and chemotherapy drugs may have the power to knock out malignancies with a one-two punch. The strategy holds promise for patients with many different kinds of cancers.

25 May 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois.

25 May 2010

REDUCE trial data published in the online version of European Urology

On 8 May an editorial about the Reduction by Dutasteride of Prostate Cancer Events trial by Fritz H. Schröder and Monique J. Roobol was published in the online version of European Urology, the scientific journal of the European Association of Urology.

25 May 2010

DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis

ARIAD Pharmaceuticals, Inc. today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to its final analysis, without modification to the study protocol.

25 May 2010

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents, and Avila Therapeutics, Inc., a biotechnology company designing targeted covalent drugs, announced today an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC).

25 May 2010

ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010.

25 May 2010

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Epeius Biotechnologies Corporation today announces the clinical results of the study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.

25 May 2010

Hawaii Pacific Health, Saint Barnabas Health Care System and XCelience achieve CEO Cancer Gold Standard

Hawaii Pacific Health, Saint Barnabas Health Care System N.J., and XCelience LLC, have received CEO Cancer Gold Standard™ accreditation, recognizing the commitment of these organizations to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

25 May 2010

AlphaMed Press earns CEO Cancer Gold Standard accreditation

AlphaMed Press has received CEO Cancer Gold Standard™ accreditation, recognizing the organization's commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

25 May 2010

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

Vical Incorporated announced today that the company is collaborating with leading pediatric infectious disease researchers Stuart P. Adler, M.D., and Michael A. McVoy, Ph.D., of Virginia Commonwealth University under a five-year, approximately $4.0 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

25 May 2010

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its Allston, Mass., manufacturing facility and will turn over to the federal government $175 million in unlawful profits from the sale of products that were made at the plant, the U.S. Food and Drug Administration announced today.

25 May 2010

Shrink files patent related to rapid prototyping system for manufacture of Lab-on-a-Chip devices

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that patent applications related to its rapid prototyping system for the manufacture of microfluidic chips, or Lab-on-a-Chip (LOC) devices, have been filed.

25 May 2010

LEO Pharma implements Cegedim Dendrite's Mobile Intelligence CRM solution in 6 Asia-Pacific countries

Cegedim Dendrite today announced that LEO Pharma has implemented Mobile Intelligence™, Cegedim Dendrite's flagship Customer Relationship Management (CRM) solution using a Software as a Service (SaaS) delivery model, in six countries in the Asia-Pacific region. LEO Pharma is a global pharmaceutical company specializing in dermatology and critical care and Cegedim Dendrite is the world's leading provider of Pharmaceutical CRM solutions with a 35 percent global market share.

25 May 2010

New research finding may change direction of vaccine research for M. tuberculosis

Scientists at NYU Langone Medical Center have discovered that the strategy of "immune evasion" common to many viruses, bacteria and parasites, is uncommon to M. tuberculosis where the antigens remain strikingly unchanged and homogenous. The study published in Nature Genetics on May 23, 2010, suggests that M. tuberculosis antigens do not mutate because they hope to be recognized by the body's immune system- perhaps because the host immune mechanism that leads to the typical lung destruction and cough can contribute to the spread of the disease.

25 May 2010

Rush University Medical Center uses Mini TightRope procedure to treat bunions

A less invasive, surgical treatment for bunions known as the Mini TightRope procedure is being used at Rush University Medical Center to correct bunions, or hallux valgus, a common, often painful deformity in which the big toe is angled in toward the smaller toes.

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Genzyme finalizes terms for consent decree regarding Allston manufacturing plant

Genzyme Corporation announced today that the terms for the consent decree regarding the Allston manufacturing plant have been finalized. These terms are in line with the company's expectations announced last month. The consent decree is subject to approval by the United States District Court for the District of Massachusetts.

25 May 2010

Cancer News and Research

Latest Cancer News and Research

HHS 'special mailing' on health law's immediate Medicare benefits sparks GOP grumbles

BIO praises Obama Administration’s dissemination of Therapeutic Discovery Project Program

CCO announces 2010 Research Chairs program

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

REDUCE trial data published in the online version of European Urology

DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Hawaii Pacific Health, Saint Barnabas Health Care System and XCelience achieve CEO Cancer Gold Standard

AlphaMed Press earns CEO Cancer Gold Standard accreditation

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

Genzyme signs consent decree of permanent injunction, agrees to disgorgement

Shrink files patent related to rapid prototyping system for manufacture of Lab-on-a-Chip devices

LEO Pharma implements Cegedim Dendrite's Mobile Intelligence CRM solution in 6 Asia-Pacific countries

New research finding may change direction of vaccine research for M. tuberculosis

Rush University Medical Center uses Mini TightRope procedure to treat bunions

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Genzyme finalizes terms for consent decree regarding Allston manufacturing plant

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in